Ascentage Pharma Group International 6855.HK · HKD

Its shares trade on HKEX under the ticker 6855.HK. It has been listed since 28 October 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥652.2m and a net loss of CN¥1.41bn. At that date it held total assets of CN¥4.62bn and shareholders' equity of CN¥1.55bn.

Ascentage Pharma Group International Co., Ltd. develops and produces pharmaceutical products. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2019-10-28. The firm focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The firm's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The firm conducts businesses within the domestic market and to overseas markets, including the United States.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Dajun YangExecutive Chairman of the Board, Chief Executive Officer, Co-Founder, since 2017CN¥4.8m
• Mr. Thomas KnappSenior Vice President, General Counsel
• Mr. Jin CaoHead - Finance
• Mr. Raymond KmetzChief Business Officer
• Dr. Yifan ZhaiChief Medical Officer
• Ms. Charmayne ChanCompany Secretary
• Dr. Shaomeng WangNon-Executive Director, Co-FounderCN¥1.2m
• Ms. Marina BozilenkoIndependent Non-Executive Director
• Dr. Marc LippmanIndependent Non-Executive Director
• Dr. Dazhong LuIndependent Non-Executive DirectorCN¥25,000
• Mr. Wei RenIndependent Non-Executive DirectorCN¥502,000
• Dr. David SidranskyIndependent Non-Executive DirectorCN¥510,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.